Rini B - Search Results

1

Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.

Vrdoljak E, Rini B, Schmidinger M, Omrčen T, Torday L, Szczylik C, Sella A. Vrdoljak E, et al. Among authors: rini b. Anticancer Drugs. 2013 Jun;24(5):431-40. doi: 10.1097/CAD.0b013e328360335f. Anticancer Drugs. 2013. PMID: 23511427 Review.

2

Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial.

Rini BI, Stadler WM, Spielberger RT, Ratain MJ, Vogelzang NJ. Rini BI, et al. Cancer. 1998 Apr 1;82(7):1352-8. doi: 10.1002/(sici)1097-0142(19980401)82:7<1352::aid-cncr19>3.0.co;2-5. Cancer. 1998. PMID: 9529028 Clinical Trial.

3

A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.

Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. Desai AA, et al. Cancer. 2002 Oct 15;95(8):1629-36. doi: 10.1002/cncr.10847. Cancer. 2002. PMID: 12365009 Free article. Clinical Trial.

4

A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.

Rini BI, Weinberg V, Small EJ. Rini BI, et al. Cancer. 2005 Feb 1;103(3):553-8. doi: 10.1002/cncr.20795. Cancer. 2005. PMID: 15612026 Free article. Clinical Trial.

5

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Motzer RJ, et al. J Clin Oncol. 2006 Jan 1;24(1):16-24. doi: 10.1200/JCO.2005.02.2574. Epub 2005 Dec 5. J Clin Oncol. 2006. PMID: 16330672 Clinical Trial.

6

Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.

Rini BI, Weinberg V, Dunlap S, Elchinoff A, Yu N, Bok R, Simko J, Small EJ. Rini BI, et al. Cancer. 2006 Feb 1;106(3):566-75. doi: 10.1002/cncr.21661. Cancer. 2006. PMID: 16369983 Free article. Clinical Trial.

7

Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.

Shaheen PE, Rini BI, Bukowski RM. Shaheen PE, et al. Clin Genitourin Cancer. 2006 Jun;5(1):78-81. doi: 10.3816/CGC.2006.n.021. Clin Genitourin Cancer. 2006. PMID: 16859583

8

A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.

Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, Barrier R, Small EJ; Cancer and Leukemia Group B. Stadler WM, et al. Among authors: rini b. Cancer. 2006 Sep 15;107(6):1273-9. doi: 10.1002/cncr.22117. Cancer. 2006. PMID: 16909426 Free article. Clinical Trial.

9

Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.

Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Bukowski RM. Choueiri TK, et al. Cancer. 2006 Dec 1;107(11):2609-16. doi: 10.1002/cncr.22290. Cancer. 2006. PMID: 17075879 Free article. Clinical Trial.

10

Molecularly targeted therapy in renal cell carcinoma: where do we go from here?

Rini BI. Rini BI. Expert Rev Anticancer Ther. 2006 Dec;6(12):1753-60. doi: 10.1586/14737140.6.12.1753. Expert Rev Anticancer Ther. 2006. PMID: 17181489 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

529 results

Search Page

Filters